“BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA”. Mediterranean Journal of Hematology and Infectious Diseases 8 (February 10, 2016): e2016011. Accessed May 12, 2026. https://www.mjhid.org/mjhid/article/view/2016.011.